InMed Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
INM Nasdaq 2836 www.inmedpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for InMed Pharmaceuticals Inc.

InMed Announces Results of 2025 Annual General and Special Meeting - Dec 17th, 2025 6:00 pm
InMed Provides Update on BayMedica Commercial Business - Dec 12th, 2025 3:31 pm
Life Sciences Virtual Investor Forum Agenda Announced for December 11th - Dec 9th, 2025 6:35 am
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901 - Nov 18th, 2025 5:30 am
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update - Nov 6th, 2025 2:51 pm
InMed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors - Oct 16th, 2025 6:30 am
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors - Oct 9th, 2025 6:30 am
InMed Pharmaceuticals reports FY25 EPS ($8.36) vs ($20.14) last year - Sep 24th, 2025 6:45 am
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update - Sep 23rd, 2025 6:30 am
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing - Sep 18th, 2025 6:35 am
InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025 - Sep 16th, 2025 11:39 am
Life Science Virtual Investor Forum Agenda Announced for September 18th - Sep 16th, 2025 9:57 am
InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Sep 5th, 2025 11:33 am
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 - Jul 28th, 2025 5:00 am
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules - Jun 27th, 2025 5:00 am
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Jun 25th, 2025 6:00 am
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study - Jun 24th, 2025 5:00 am
InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA - Jun 13th, 2025 2:30 pm
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update - May 12th, 2025 4:00 pm
InMed Pharmaceuticals Second Quarter 2025 Earnings: US$3.65 loss per share (vs US$3.71 loss in 2Q 2024) - Feb 14th, 2025 4:27 am